Skip to main content
Figure 3 | Journal of Translational Medicine

Figure 3

From: Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells

Figure 3

Activation of BsAb-IR expressing T-cells depends on the specific engagement and crosslinking of immunoreceptors. A. IFNg production by BsAb-IR-z and untransduced T-cells stimulated with immobilized anti-BsAB-IR antibody (MOV18), anti-CD20 rutixumab, or mouse IgG1. Overnight culture supernatants were analyzed for human IFNg cytokine by ELISA. Concentration of IFNg is expressed as mean ± SEM in pg/ml from triplicate wells. B. Intracellular IFNg staining of BsAb-IR-z and untransduced T-cells following 6 hr stimulation with 0.1ug of an immobilized anti-BsAb-IR (MOV18) or IgG1 antibody, or cultured in a growth media supplemented with folic acid (40 mg/l) for 12 hr.

Back to article page